These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 4950775)

  • 1. Immunogenicity of living attenuated shigellae.
    Serény B; Tenner C; Rácz P
    Acta Microbiol Acad Sci Hung; 1971; 18(4):239-45. PubMed ID: 4950775
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunogenic value of live, inactivated and cell-free dysentery vaccines.
    Meitert T; Sulea IT; Gogulescu L; Baron E; Tempea C; Istrati G
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):103-7. PubMed ID: 4613127
    [No Abstract]   [Full Text] [Related]  

  • 3. [Safety, reactivity and effectiveness testing of live shigella flexneri vaccines in laboratory animals and children (author's transl)].
    Sergeev VV; Elkina SI; Solodnikov YP; Shuster BY; Sergeeva GS; Bulk VF; Bobkin SV
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):121-8. PubMed ID: 4216247
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral immunization against dysentery.
    Kétyi I; Rauss K; Vertényi A
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):81-5. PubMed ID: 4613142
    [No Abstract]   [Full Text] [Related]  

  • 5. Construction and evaluation of a virG thyA double mutant of Shigella flexneri 2a as a candidate live-attenuated oral vaccine.
    Yoshikawa M; Sasakawa C; Okada N; Takasaka M; Nakayama M; Yoshikawa Y; Kohno A; Danbara H; Nariuchi H; Shimada H
    Vaccine; 1995; 13(15):1436-40. PubMed ID: 8578822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live dysentery vaccine "Vadizen" (T32-Istrati) immunogenicity against Shigella-like challenge in animals.
    Ciudin L; Meitert T; Pencu E; Gheorghe G; Tonciu M; Mihai I; Manase R
    Arch Roum Pathol Exp Microbiol; 1986; 45(3-4):247-56. PubMed ID: 3300598
    [No Abstract]   [Full Text] [Related]  

  • 7. Antidysentery immunoprophylaxis in the light of current data about the pathogenicity of Shigella and the antidysentery immunity.
    Meitert T
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):195-230. PubMed ID: 6443688
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
    Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
    Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cellular and humoral immune response after administration to the guinea pig of Shigella flexneri 2a T32--Istrati vaccinal strain by different routes.
    Meitert T; Radu I; Ciudin L; Pencu E; Tonciu M
    Arch Roum Pathol Exp Microbiol; 1978; 37(3-4):267-76. PubMed ID: 395927
    [No Abstract]   [Full Text] [Related]  

  • 10. [Live shigella flexneri 2a and shigella sonnei vaccines (author's transl)].
    Belaia IuA; Gekker VD; Kuz'min SN; Sergeeva NS
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):63-9. PubMed ID: 4216253
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunity of the guinea pig's eye after vaccination with Shigella sonnei phase I antigen.
    Kerekes L
    Acta Microbiol Acad Sci Hung; 1976; 23(4):353-8. PubMed ID: 799899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental salmonellosis conjunctivitis and keratitis in guinea pigs].
    Voĭno-Iasenetskiĭ MV; Ismailov EM; Dragunskaia EM; Ravdonikas LE
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Jul; (7):102-5. PubMed ID: 331788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery.
    Phalipon A; Sansonetti P
    Biologicals; 1995 Jun; 23(2):125-34. PubMed ID: 7546655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati).
    Meitert T; Pencu E; Ciudin L; Tonciu M
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):251-78. PubMed ID: 6400299
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of the keratoconjunctival model in guinea pigs for quantitative assessment of the immunogenicity of dysentery antigens].
    Korneeva SA; Solov'eva OG
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Oct; (10):139-40. PubMed ID: 335731
    [No Abstract]   [Full Text] [Related]  

  • 16. Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.
    Bernardini ML; Arondel J; Martini I; Aidara A; Sansonetti PJ
    Infect Immun; 2001 Feb; 69(2):1072-83. PubMed ID: 11160004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shigellosis: the current status of vaccine development.
    Kweon MN
    Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose.
    Mel DM; Arsic BL; Radovanovic ML; Litvinjenko SA
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):109-14. PubMed ID: 4613128
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of an auxotrophic oral live Shigella flexneri vaccine.
    Lindberg AA; Kärnell A; Stocker BA; Katakura S; Sweiha H; Reinholt FP
    Vaccine; 1988 Apr; 6(2):146-50. PubMed ID: 2838986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella.
    DuPont HL; Hornick RB; Snyder MJ; Libonati JP; Formal SB; Gangarosa EJ
    J Infect Dis; 1972 Jan; 125(1):5-11. PubMed ID: 4550417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.